- Avant Technologies (OTCQB:AVAI) and Ainnova Tech are finalizing the prototype for an automated retinal camera.
- The device integrates seamlessly with the Vision AI platform for quick disease risk detection and reporting.
- Ai-nova Acquisition Corp holds global licensing rights for the technology's development and marketing.
Avant Technologies Inc. (OTCQB:AVAI) and its joint venture partner, Ainnova Tech, Inc., are in the final prototyping stages of an innovative automated retinal camera. This device, developed by Ai-nova Acquisition Corp (AAC), seeks to revolutionize the market with its lower cost and ease of use compared to existing fundus cameras.
The camera will work in conjunction with Ainnova's Vision AI software platform, which is capable of detecting early markers of several diseases such as diabetic retinopathy, glaucoma, macular edema, and others like cardiovascular disease and type 2 diabetes. Notably, the Vision AI platform generates detailed risk reports within seconds from the images captured by the retinal camera.
Ainnova and Avant's joint venture, AAC, holds the exclusive global licensing rights for the development, maintenance, and marketing of Ainnova's cutting-edge technology portfolio. This strategic collaboration aims to capture a significant market share by providing an affordable and comprehensive solution for early disease detection using artificial intelligence.
The newly developed camera promises seamless integration with the Vision AI platform, allowing for efficient patient referrals and early disease management. As the device moves closer to full-scale development, it represents a significant step forward in the healthcare technology sector, offering a broader preventive screening approach beyond just eye conditions.
